Caprock Group, Inc. Exelixis, Inc. Transaction History

Caprock Group, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 23, 2023	BUY	$14.96 - $17.39 $3,410 - $3,964	228 Added 1.1%	20,945 $0
Q3 2022 Nov 07, 2022	BUY	$15.68 - $22.27 $1,442 - $2,048	92 Added 0.45%	20,717 $325,000
Q2 2022 Jul 26, 2022	BUY	$17.44 - $23.16 $1,744 - $2,316	100 Added 0.49%	20,625 $429,000
Q4 2021 Jan 18, 2022	BUY	$15.84 - $21.88 $153,838 - $212,498	9,712 Added 89.82%	20,525 $375,000
Q3 2021 Oct 07, 2021	BUY	$16.3 - $21.14 $176,251 - $228,586	10,813 New	10,813 $229,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Caprock Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Caprock Group, Inc. with notifications on news.